Patient preference of ranibizumab treatment regimen for neovascular age-related macular degeneration - monthly injections versus pro re nata.
Graefes Arch Clin Exp Ophthalmol
; 252(1): 31-4, 2014 Jan.
Article
en En
| MEDLINE
| ID: mdl-23860798
ABSTRACT
PURPOSE:
To identify preference of treatment regimen in patients with anti-VEGF therapy for neovascular age-related macular degeneration (AMD) in real life.METHODS:
A cross-sectional study was conducted in 200 patients receiving ranibizumab therapy on a pro re nata regimen with monthly controls. One hundred and twenty-four patients were recruited in a tertiary health care clinic, and 76 patients were recruited in a private practice. Patients were asked to respond to a 14-item questionnaire covering items such as treatment burden and preference for treatment either monthly injections or pro re nata.RESULTS:
Mean time under anti-VEGF treatment was 33.7 months, and the mean number of intravitreal injections was 17.7. Despite a high treatment burden in 60.3 % of patients, there was an acceptance rate for monthly examinations or injections of 93 %. The proportion of patients who favoured a PRN regimen was 53.0 %, whereas 37.9 % of patients favoured continuous injections. Major concern was recurrent disease activity in 54.5 %.CONCLUSION:
We identified two groups of patients of considerable size who would prefer either monthly injections or as-required. Overall, there was a high acceptance rate despite a high treatment burden. Nevertheless, efforts should be undertaken to improve examination and injection procedures and to consider the patient's preference for a treatment regimen.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Inhibidores de la Angiogénesis
/
Degeneración Macular Húmeda
/
Prioridad del Paciente
/
Anticuerpos Monoclonales Humanizados
Tipo de estudio:
Diagnostic_studies
/
Observational_studies
/
Prevalence_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Graefes Arch Clin Exp Ophthalmol
Año:
2014
Tipo del documento:
Article
País de afiliación:
Alemania